← Back to Search

Provider intervention for Sickle Cell Disease (DISPLACE Trial)

N/A

Waitlist Available

Led By Julie Kanter, MD

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline-2 years

Awards & highlights

DISPLACE Trial Summary

This trial is testing whether new implementation strategies can improve adherence to and implementation of stroke screening in children with sickle cell anemia.

Eligible Conditions

Sickle Cell Disease

DISPLACE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline-2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline-2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline-2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

1. Change in uptake and use of the stroke prevention guidelines (STOP Protocol) as defined in the NHLBI (National Heart, Lung, and Blood Institute) 2014 Sickle Cell Disease (SCD) Guidelines by assessing stroke risk with yearly TCD screens

2. Change in uptake and use of the stroke prevention guidelines (STOP Protocol) as defined in the NHLBI 2014 SCD Guidelines by implementing chronic red cell transfusion (CRCT) in patients noted to have abnormal TCD screens.

A difference in uptake and use of the stroke prevention guidelines (STOP Protocol) as defined in the NHLBI 2014 SCD Guidelines between between implementation arms measured by assessing yearly TCD screening rates.

+1 more

Secondary outcome measures

Barriers to obtaining TCD screening

Enablers to obtaining TCD screening

DISPLACE Trial Design

2Treatment groups

Active Control

Group I: Provider interventionActive Control1 Intervention

Group II: Provider and Patient level interventionActive Control2 Interventions

A web-based application called ProviderMinder has been developed and will be used to alert providers when a patient who has been lost-to-follow-up or has missed their Sickle Stroke Screen (TCD). This will allow providers to follow up with such patients and improve screening rates. Additionally, sites will have a patient intervention of a single Sickle Stroke Screen coordinator who will interact directly with patients to schedule, reschedule, remind, and follow-up on stroke screening. This person will also act as a point of contact for any educational needs the patient may have. The second patient intervention will include the caregivers own mobile device. When Sickle Stroke Screens are scheduled the coordinator will ensure these appointments are directly put into the caregiver's mobile device calendar acting as an additional reminder for stroke screening.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor

1,590 Previous Clinical Trials

2,281,446 Total Patients Enrolled

Julie Kanter, MDPrincipal InvestigatorUniversity of Alabama at Birmingham

2 Previous Clinical Trials

6,247 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still openings for participants in this trial?

"According to records hosted on clinicaltrials.gov, the search for volunteers has been discontinued since the last update of July 7th 2022; however, there are currently 198 other trials that still require participants."

Answered by AI

How many research sites have been established to conduct this experiment?

"Patients can be recruited from various sites, such as Children's Healthcare of Atlanta in Atlanta, Arkansas Children's Research Institute in Little Rock and UCSF Benioff Children's Hospital Oakland in Oakland. An additional 15 locations are also participating."

Answered by AI

Does this trial accept participants in the senior age bracket?

"This particular trial is specifically for patients aged between 2 and 7. As a whole, 131 medical studies cater to those under 18 years old while 86 accommodate the elderly population over 65."

Answered by AI

Are there criteria that allow me to participate in this clinical research?

"This clinical trial has recruited 16 children between the ages of 2 and 7 that have been diagnosed with anemia and sickle cell. Eligibility criteria includes recognition as a SCA patient through ICD-9/ICD-10 codes, two documented medical visits at the institution from 2018 to 2019, birth year 2012 or later, and those already receiving stroke prevention therapy via CRCT being registered in Web Data Coordination Unit (WEBDCU)."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Dissemination and Implementation of Stroke Prevention Looking at the Care Environment

Julie Kanter 2020. "Dissemination and Implementation of Stroke Prevention Looking at the Care Environment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04173026.